There are currently 1538 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Connect® Myeloid Disease Registry
NCT01688011
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/25/2022
Locations: Dallas VA Medical Center, Dallas, Texas +2 locations
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Register for Updates
Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)
NCT05595031
Recruiting
The purpose of this project is to evaluate the clinical impact of the use of glucocorticoids beyond 10 days for patients with critical COVID-19 at MDMC.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/21/2022
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: Covid 19
Register for Updates
Coping, Perceived Meaning, Joy, Horizontal Civility at Work
NCT05595057
Recruiting
The aim of this study is to assess and describe employee characteristics associated with perceived horizontal inter-collegial workplace uncivil behavior within nursing services, and identify any relationships with meaning and joy in work (MJW), and assess job satisfaction.
Gender:
All
Ages:
All
Trial Updated:
10/21/2022
Locations: Methodist Dallas Medical Center, Dallas, Texas +2 locations
Conditions: Workplace Incivility, Joy, Self Efficacy
Register for Updates
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
NCT03926624
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2022
Locations: UT Southwestern, Dallas, Texas
Conditions: Leukemia, Myeloid, Acute
Register for Updates
A Study of sEphB4-HSA in Kaposi Sarcoma
NCT03993106
Recruiting
sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to learn if sEphB4-HSA will decrease the number or size of Kaposi sarcoma lesions in people.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/11/2022
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Kaposi Sarcoma
Register for Updates
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
NCT05569057
Recruiting
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SIM1811-03 in adult patients with advanced solid tumors and cutaneous T-cell lymphoma. SIM1811-03 is a first-in-class IgG1-based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/03/2022
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Advanced Solid Tumor, Cutaneous T-cell Lymphoma (CTCL)
Register for Updates
Late Onset Alzheimer's Disease
NCT05010603
Recruiting
The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.
Gender:
All
Ages:
55 years and above
Trial Updated:
09/16/2022
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Alzheimer Disease
Register for Updates
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
NCT04375813
Recruiting
eRapa (encapsulated rapamycin) will be investigated for secondary prevention in patients with diagnosed non-muscle invasive bladder cancer (NMIBC) through a phase II double-blind randomized controlled trial of long-term (one year) prevention with eRapa versus placebo. The primary hypothesis is that eRapa decreases the risk of cancer relapse for patients with NMIBC. Secondary hypotheses are that eRapa can improve certain immune parameters and improve cognition and physical function without advers... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/14/2022
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Non-muscle Invasive Bladder Cancer
Register for Updates
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
NCT04666129
Recruiting
This study is being conducted to assess the safety and tolerability of relugolix with other agents approved for use in combination with androgen deprivation therapy (ADT) for a 12-week treatment period and an additional 40-week safety extension period in men with prostate cancer, either metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic or metastatic castration-resistant prostate cancer (nmCRPC or mCRPC).
Gender:
Male
Ages:
18 years and above
Trial Updated:
09/02/2022
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
Register for Updates
Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System
NCT05406167
Recruiting
The purpose of this prospective cohort study is to assess clinical and quality of life measures as well as to define the severity of adverse effects for the use of the RefleXion system to deliver intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), in standard of care (SOC) use in the treatment of local,loco-regionally advanced, and oligometastatic malignancies. In addition, patient costs and charges will be analyzed to quantify the health economic impact of this modal... Read More
Gender:
All
Ages:
All
Trial Updated:
08/05/2022
Locations: UT Southwestern, Dallas, Texas
Conditions: Cancer, Cancer Central Nervous System, Cancer Thoracic, Cancer, Gastrointestinal, Cancer Gynecologic, Cancer, Genito-Urinary, Cancers Lymphatic, Cancer Head and Neck
Register for Updates
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)
Gender:
All
Ages:
18 years and above
Trial Updated:
08/03/2022
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Register for Updates
Non-invasive Characterization of Systemic Microvascular Reactivity by Near-infrared Diffuse Optical Spectroscopy in COVID-19 Patients
NCT04689477
Recruiting
The purpose of this study is to characterize microvascular reactivity on the forearm muscle using non-invasive near-infrared spectroscopy in critically ill COVID-19 patients, and to correlate its alterations with 28-day mortality in ICU COVID-19 patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/27/2022
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: COVID-19, Endothelial Function
Register for Updates